Synlogic stock.

The latest price target for . Synlogic (NASDAQ: SYBX) was reported by Chardan Capital on August 11, 2023.The analyst firm set a price target for $6.00 expecting SYBX to rise to within 12 months (a ...

Synlogic stock. Things To Know About Synlogic stock.

Nov 9, 2023 · Synlogic is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information. Mar 28, 2023 · CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European ... Mar 28, 2023 · CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European ... What is the target price for Synlogic (SYBX) stock? A. The latest price target for Synlogic ( NASDAQ: SYBX) was reported by Chardan Capital on Friday, August 11, 2023. The analyst firm set a price ...

Synlogic Inc () Stock Market info Recommendations: Buy or sell Synlogic stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Synlogic share forecasts, stock quote and buy / sell signals below.According to present data Synlogic's SYBX shares and potentially its market environment have been in a bullish …About Synlogic. Synlogic ™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways.CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...

6.12%. $26.33M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low …

٢٨‏/٠٨‏/٢٠١٧ ... New York Stock Exc... ... No photo description available. Bloomberg. 󱢏. Media ...Upcoming Industry and Banking Conferences. Synlogic will participate in the banking and industry conferences listed below in early 2022. Recorded presentations will be available at https://investor.synlogictx.com.. H.C. Wainwright BIOCONNECT Virtual Conference. Synlogic will present a corporate update at the H.C. Wainwright …On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00. Business News - Latest Headlines on CNN Business - CNN

Dec 15, 2022 · Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash ...

Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...

Synlogic ( NASDAQ: SYBX) on Wednesday said it will implement a 1-for-15 reverse stock split of its common stock, effective September 27. The reverse stock split is primarily intended to bring the ...Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...To take any of these actions regarding your Synlogic stock, please contact the American Stock Transfer & Trust Company, LLC, Synlogic’s transfer agent. Some of these requests may involve a fee. American Stock Transfer & Trust Company (800) 937-5449 (Toll-free) (718) 921-8124 (International)Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ...View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Synlogic Stock (NASDAQ:SYBX), Quotes and News Summary benzinga.com - February 11 at 9:36 AM Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.

Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. What is Synlogic's consensus rating and price target? According to the issued ratings of 2 analysts in the last year, the consensus rating for Synlogic stock is Buy based on the current 2 buy ratings for SYBX. The average twelve-month price prediction for Synlogic is $82.50 with a high price target of $90.00 and a low price target of $75.00.Synlogic Stock (NASDAQ:SYBX), Quotes and News Summary benzinga.com - February 11 at 9:36 AM Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ... CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...

CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Mirna holding approximately 32% of the outstanding Mirna common stock and certain officers, directors and stockholders of Synlogic holding approximately 84% of the Synlogic capital stock (giving effect to Synlogic’s recent Series C financing) have …

Dec 1, 2023 · According to 2 stock analysts, the average 12-month stock price forecast for Synlogic stock is $82.5, which predicts an increase of 3,122.66%. The lowest target is $75 and the highest is $90. On average, analysts rate Synlogic stock as a strong buy. Synlogic has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on SYBX's earnings history.About Synlogic. Synlogic ™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.About Synlogic. Synlogic ™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways.Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3. October 18, 2022.

١٣‏/٠٦‏/٢٠١٩ ... ... shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The ...

Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...

Over the past week, Wood has been accumulating shares of Verve Therapeutics (VERV-6.12%) for her firm's flagship growth stock fund, the ARK Innovation ETF (ARKK 0.43%), and the biotech-focused ARK ...But Ginkgo simultaneously invested $80 million in Synlogic at a sizable premium to its stock price at the time. In effect, the money took a round trip, starting as cash in Ginkgo’s bank account ...Support, Risk & Stop-loss for Synlogic Inc stock. On the downside, the stock finds support just below today's level from accumulated volume at $2.14 and $2.07. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.Synlogic has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on SYBX's earnings history.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Figure 5: Synlogic Stock Chart (source: finviz) Thus, Synlogic looks like a good value at current levels, although, obviously, still a high-risk investment due to the early stages of its assets.Mar 20, 2023 · About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ... Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Synlogic, Inc. (SYBX) Stock Price, Quote, News & Analysis Black Friday is here! Save 45% on Premium AND Alpha Picks now » SYBX Synlogic, Inc. Stock Price …Synlogic’s pipeline is fueled by its Synthetic Biotic platform, which applies precision engineering to well-characterized probiotics. This creates GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for diseases such as PKU and HCU, both inborn errors of metabolism, as well as others in …

Synlogic, Inc. (SYBX) is a biotechnology company that is publicly traded on the NASDAQ stock exchange. As a publicly traded company, Synlogic is owned by its shareholders, who can buy and sell shares of the company on the open market.Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases.The first big announcement that META stock fans will want to note is details on the Meta Quest 3. This is the company’s VR headset that offers 10x the number of pixels as the Meta Quest 2 for $500.Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...Instagram:https://instagram. best day to sell stockpaas tickercaptrust financialhigh dividend reits 2023 But Ginkgo simultaneously invested $80 million in Synlogic at a sizable premium to its stock price at the time. In effect, the money took a round trip, starting as cash in Ginkgo’s bank account ... top financial advisors in columbus ohioinvesco qqq fees Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuriaCAMBRIDGE, Mass., March 20 ... cara therapeutics inc Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …